Ocrelizumab helps control MS in Black & Hispanic adults

Credibility

Interest

Share:2 min read

Key Takeaway

Two years of ocrelizumab treatment helped control MS activity in Black and Hispanic adults, with most people avoiding relapses and disability progression.

What They Found

Researchers treated 182 self-identified Black and Hispanic adults with relapsing MS with ocrelizumab for two years and watched how their disease behaved. By one year, about half of participants showed no signs of active disease across relapses, disability worsening, and MRI scans. Almost all participants (about 95%) did not have confirmed disability progression over 24 weeks or a clinical relapse during the first year. MRI scans showed most people had no new contrast-enhancing lesions (a sign of active inflammation), though about half had no new or growing T2 lesions (another MRI sign of disease change). Some side effects happened: serious side effects were uncommon (8%), a few people stopped treatment (2%), and infusion reactions or stomach problems were more common in some groups but generally manageable.

Who Should Care and Why

People with relapsing MS from Black and Hispanic communities and their caregivers should care because this study looked specifically at people like them, who are often underrepresented in research. If you are considering ocrelizumab, these results suggest it can reduce relapses and slow short-term disability for many people, which could mean fewer flare-ups and more stable daily life. Caregivers may notice fewer sudden needs for extra help if relapses are prevented, similar to how fixing a leaky roof can reduce emergency repairs. Doctors and MS care teams can use this information to discuss treatment options more confidently with Black and Hispanic patients. The findings do not guarantee results for everyone, but they add useful evidence that ocrelizumab worked similarly in these groups as in earlier trials.

Important Considerations

This was an open-label study without a comparison group, so we cannot be certain how much better ocrelizumab is than other options from this study alone. The main results focused on the first year, and longer-term effects beyond two years are not answered here. Side effects varied between groups and individual risk or other health conditions could change how safe or helpful the treatment is for a given person.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Clinical Trials Treatment Updates MS Genetics

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Annals of neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News